HRT Benefits and Risks: What the Real Numbers Say

Is HRT safe? The short answer depends on your age and timing

For most healthy women under 60, or within 10 years of their last period, yes. The Menopause Society's 2022 position statement says the balance favors treatment for bothersome hot flashes and for preventing bone loss.

The picture shifts if you start later. After 60, or more than 10 years past menopause, the same statement calls the balance less favorable. The extra cases of heart disease, stroke, blood clots and dementia add up faster at older ages.

Much of the fear traces back to the Women's Health Initiative, or WHI, the largest placebo-controlled trial of hormone therapy. The FDA points out that its volunteers averaged 63 years old. Most women start HRT for symptoms somewhere between 45 and 55.

Safety also depends on what you take. The Menopause Society names the type, dose, duration, route, timing and whether you need a progestogen. A progestogen is the second hormone that protects the lining of the uterus, if you still have one.

In women who started at 50 to 59, each serious risk in the WHI came to about 10 extra cases or fewer per 10,000 women a year. If you want the mechanics first, how HRT works explains what each hormone does. Still having periods? Hormone therapy in perimenopause covers that earlier window.

Benefits of HRT: the effects you can feel, with placebo numbers

Hot flashes and night sweats

Hot flashes are where HRT is strongest. A Cochrane review of placebo-controlled trials of oral HRT found about 75% fewer weekly hot flashes on HRT than on placebo.

Placebo was not nothing, though. In the same review, hot flashes in the placebo groups still fell by about 58% from where they started. Night sweats improve too, since they are hot flashes that strike during sleep.

The Menopause Society calls HRT the most effective treatment for hot flashes and night sweats. Pills, patches and gels work about equally well for hot flashes.

If you can't or won't take hormones, non-hormonal prescriptions exist. Veozah vs HRT compares the best-known one, and perimenopause hot flashes covers why they happen in the first place.

Sleep

Sleep tends to improve mostly because night sweats stop waking you up. The Menopause Society says HRT improves sleep in women with bothersome night sweats by cutting nighttime awakenings. Estrogen may also help sleep on its own, but that evidence is weaker.

Vaginal dryness, painful sex and urinary symptoms

Doctors call this cluster genitourinary syndrome of menopause, or GSM. It covers dryness, burning, pain during sex, urgency and repeat urinary tract infections. Unlike hot flashes, it tends to get worse with time, not better.

Low-dose vaginal estrogen treats it well, and very little of the hormone reaches your bloodstream. Trials also found fewer repeat urinary infections with vaginal estrogen, but not with estrogen pills.

One surprise is bladder leaks. Systemic HRT, meaning pills, patches or gels that treat the whole body, does not fix them. It may even make leaks with coughing or sneezing more likely.

Bone strength and fractures

Estrogen slows the bone loss that speeds up after menopause. Across all ages in the WHI, each hormone regimen led to about 6 fewer hip fractures per 10,000 women a year.

HRT is FDA-approved to prevent osteoporosis, not to treat it once you have it. Bone density drifts back to where it started within one to two years of stopping.

Side benefits seen in trials, not reasons to start

• Type 2 diabetes: across all ages, the WHI combined arm had about 16 fewer new cases per 10,000 women a year. HRT is not approved for this.
• Colon cancer: the combined arm had fewer colorectal cancers, but the ones found were more advanced. Deaths from colon cancer did not differ.
• Mood in perimenopause: estrogen has shown an antidepressant effect in some perimenopausal women with depression. It is not approved to treat mood.
• Weight: women on HRT in the trials did not gain more weight than women on placebo. What HRT actually changes covers the body-composition side.

HRT risks and benefits in real numbers

Percentages can make HRT sound scarier or safer than it is. Counting actual cases is clearer.

The figures below are WHI results for women who started at ages 50 to 59. The Menopause Society adapted them from the 2013 WHI follow-up in JAMA. Each one is extra or fewer cases per 10,000 women per year, compared with placebo.

To translate, 10 per 10,000 is the same as 1 in 1,000.

Estrogen plus progestogen, for women with a uterus

• Blood clots in a leg vein: about 10 more
• Blood clots in the lung: about 6 more
• Stroke: about 5 more
• Heart disease events: about 5 more, a difference that was not statistically clear
• Breast cancer: about 6 more
• Fractures of any kind: about 25 fewer
• New type 2 diabetes: about 11 fewer
• Deaths from any cause: about 10 fewer

Estrogen alone, for women without a uterus

• Blood clots in a leg vein: about 5 more
• Blood clots in the lung: about 3 more
• Stroke: about 1 fewer
• Heart disease events: about 11 fewer
• Breast cancer: about 5 fewer
• Colorectal cancer: about 3 fewer
• Fractures of any kind: about 16 fewer
• New type 2 diabetes: about 26 fewer
• Deaths from any cause: about 11 fewer

Two things stand out. Estrogen alone looks gentler than the combination on almost every line. And in one analysis of women 50 to 59, clots on the combination were the only risk that rose significantly.

Keep in mind that the WHI tested one oral combination, conjugated estrogens with medroxyprogesterone. Today's patches, gels and body-identical progesterone were not part of it.

One risk the headlines usually skip is gallbladder disease. Across all ages in the WHI, it ran at roughly 47 to 58 extra cases per 10,000 women a year. Observational studies suggest patches carry less of this risk than pills.

Why starting later changes the math

Start after 60, or more than 10 years after menopause, and the extra cases climb. A 2015 Cochrane review found higher stroke and clot risk in late starters, with no heart benefit.

Women who started after 70 had the highest risk of all in the WHI. The memory study, covered below, shows the same pattern for dementia.

HRT and breast cancer: type, duration and progestogen all matter

This is the risk most women ask about first, so here it is plainly. The answer depends on whether you take a progestogen, which kind, and for how long.

What the randomized trial showed

In the WHI, the combined pill led to about 9 extra breast cancers per 10,000 women a year across all ages. That is less than 1 extra case per 1,000 women per year.

The Menopause Society puts it another way: about 3 extra cases per 1,000 women after five years on that combination.

The extra risk became visible after about three to five years of combined use. For scale, the statement compares it to drinking a little more than one glass of wine a day, or to obesity and low physical activity.

Estrogen alone went the other way. Women on estrogen alone had fewer breast cancers than on placebo, a gap that became statistically clear after about 20 years of follow-up.

Breast cancer deaths were lower with estrogen alone. With the combination, they did not differ significantly from placebo.

What the largest observational study found

The Collaborative Group analysis in The Lancet pooled studies from around the world in 2019. It linked every type of HRT except vaginal estrogen to some extra breast cancer risk.

Risk rose with longer use and lingered for more than 10 years after stopping. Less than a year of use added little.

Its authors estimated what five years of HRT from age 50 would add by age 69, if the link is largely causal:

• Estrogen plus a daily progestogen: about 1 extra case per 50 users
• Estrogen plus a progestogen taken part of the month: about 1 extra case per 70 users
• Estrogen alone: about 1 extra case per 200 users

Those numbers are bigger than the WHI's for two reasons. They count cancers over a 20-year window, and observational data cannot fully separate the drug from the women who choose it.

The WHI is the stronger kind of evidence because it was randomized. Its weakness is that it tested only one combination.

Does the type of progestogen matter?

Possibly. Some observational studies suggest micronized progesterone, which is identical to your body's own, is less linked to breast cancer than synthetic progestins like medroxyprogesterone. The Menopause Society says trials are needed to confirm it.

Pills and patches seem to affect breast cancer numbers about equally. Vaginal estrogen shows no effect.

In observational data, a family history of breast cancer does not appear to multiply HRT's effect. Women who have had breast cancer are generally advised against systemic HRT.

Combined HRT can also make breasts look denser on a mammogram. That can mean more callbacks and biopsies.

Patch, gel, pill or vaginal: does the form change the risk?

For blood clots, the route may matter a lot. Estrogen swallowed as a pill passes through the liver first, while patches, gels and sprays skip that first pass.

No trial has compared them head to head for clots, so the evidence is observational. The best-known study is Vinogradova and colleagues in the BMJ, using two large UK patient databases.

• Pills: oral HRT was linked to a higher risk of blood clots than no HRT.
• Patches and gels: estrogen through the skin was not linked to a measurable increase.
• The highest-risk pill: conjugated estrogens with medroxyprogesterone, the combination the WHI tested.
• Estradiol pills: a somewhat lower clot risk than conjugated estrogen pills.

The Menopause Society reads the evidence the same way. Observational studies show no rise in clots with estrogen through the skin, but comparative trials are still missing.

Stroke follows dose more than route. Lower doses of pills or patches may carry less stroke risk, again from observational data.

Low-dose vaginal estrogen is its own category. Very little reaches the bloodstream, and long-term studies have not linked it to heart problems or cancer. Its boxed warning is gone from the updated labels.

Compounded bioidentical hormones, including pellets, are mixed to order and are not FDA-approved. The Menopause Society flags uneven dosing, possible impurities and missing safety data. FDA-approved bioidentical estradiol and progesterone already exist as pills, patches and gels.

Prices differ by form too, and pills vs patches vs injections lays them out.

What the FDA changed in February 2026, and what it kept

On February 12, 2026, the FDA approved new labels for a first group of six HRT products. The new labels shrink the boxed warning, the FDA's most prominent safety alert, often called a black box.

The six were Bijuva, Cenestin, Divigel, Enjuvia, Estring and Prometrium, according to the FDA's list of updated labels. The process started in November 2025, when the FDA asked companies to revise their labels.

What came out of the boxed warning:

• Heart disease and stroke: the cardiovascular lines are gone from the box.
• Breast cancer: gone from the box.
• Probable dementia: gone from the box and from the label as a whole.
• Lowest dose for the shortest time: the FDA asked companies to drop this line as well. Our guide to the lowest HRT dose explains what dosing looks like now.

What stayed or was added:

• Endometrial cancer: systemic estrogen-alone products keep a boxed warning about cancer of the uterus lining. It applies when a woman with a uterus takes estrogen without a progestogen.
• Heart and breast cancer warnings: still in the label, just no longer in the box.
• A line on timing: updated labels say to consider starting in women under 60 or within 10 years of menopause.
• WHI data for women 50 to 59: now printed in the labels of systemic products.

This is a rollout, not a switch. The FDA said 29 companies had submitted revised labels, and in October 2026 its list still showed only the first six products.

Older labels are still in circulation. In October 2026, the DailyMed label database still showed the full old boxed warning on Premarin tablets and the Climara patch.

The Menopause Society backed removing the box from low-dose vaginal estrogen. It added that systemic estrogen still carries risks for some women, lower for younger women who start close to menopause.

The label change did not create new evidence. It changed how the existing WHI data is presented, with more weight on women who start near menopause.

HRT and dementia: what the trials actually show

Headlines swing both ways on this one. Some say HRT causes dementia, others that it prevents Alzheimer's. The trials in women who start near menopause support neither claim.

• [WHIMS](https://pubmed.ncbi.nlm.nih.gov/12771112/), women 65 and older: the combined pill doubled probable dementia, about 23 extra cases per 10,000 women a year. Estrogen alone did not raise it significantly.
• [KEEPS](https://pubmed.ncbi.nlm.nih.gov/26035291/), women around 52: up to four years of estrogen pills or patches with progesterone neither helped nor hurt memory and thinking.
• [ELITE](https://pubmed.ncbi.nlm.nih.gov/27421538/), early versus late starters: oral estradiol had no effect on memory or thinking, whether started soon after menopause or a decade or more later.

A 2023 Danish registry study in the BMJ pulls the other way. Women aged 50 to 60 who used estrogen plus progestogen were more often diagnosed with dementia later, even when they started at 55 or younger.

That study was observational. Its authors said more research is needed to tell whether the link is a real drug effect or reflects something about the women who needed HRT.

The Menopause Society's position is plain. HRT is not recommended at any age to prevent or treat memory decline or dementia.

Midlife brain fog is a different question from dementia. Perimenopause brain fog covers what drives it and what helps.

HRT is not heart protection

You may have read that starting HRT early protects your heart. That is not what the FDA or The Menopause Society says.

The signals are mixed. In women 50 to 59, estrogen alone came with fewer heart events than placebo, and the combination with slightly more. Neither difference was statistically clear.

Studies of artery markers split too. ELITE found estradiol slowed artery-wall thickening when started within six years of menopause, but KEEPS found no effect on early artery disease.

That falls well short of a heart treatment. The Menopause Society notes HRT is not approved to prevent heart disease. The FDA patient leaflet for estrogen says not to use it to prevent heart disease, heart attacks or strokes.

The U.S. Preventive Services Task Force goes further. It recommends against HRT to prevent chronic disease in women without symptoms, though that advice does not cover treating hot flashes.

Heart prevention still runs through blood pressure, cholesterol, blood sugar and not smoking. HRT is for symptoms and bone.

HRT pros and cons at a glance

Here is the trade-off in one place, for a healthy woman under 60.

• Pro: the most effective treatment for hot flashes and night sweats.
• Pro: fewer night wakings when night sweats are the cause.
• Pro: prevents bone loss and lowers fracture risk while you take it.
• Pro: low-dose vaginal estrogen treats dryness and painful sex with little hormone in the blood.
• Pro: fewer new diabetes cases in the WHI, as a side effect rather than a reason.
• Con: a small rise in blood clots, lower with patches and gels in observational studies.
• Con: with a progestogen, a small rise in breast cancer that builds after three to five years.
• Con: a small rise in stroke with the combination.
• Con: more gallbladder disease.
• Con: early side effects such as breast tenderness, bloating and spotting, covered in HRT side effects.
• Con: symptom relief and bone protection fade after you stop.

If the cons outweigh the pros for you, menopause treatment options compares the non-hormonal routes.

Who should not take HRT, and who benefits most

Current FDA estrogen labels list these as reasons not to use systemic estrogen. The list below follows the Divigel label updated in February 2026.

• Vaginal bleeding that has not been explained
• Breast cancer now or in the past
• Other cancers that estrogen can feed
• A blood clot in a leg or lung, now or in the past
• A stroke or heart attack, now or in the past
• Liver disease or poor liver function
• Inherited clotting disorders, such as protein C, protein S or antithrombin deficiency
• A past allergic reaction to the product

Other factors don't rule HRT out but do shift the choice. A personal or family history of clots, stroke, heart disease or breast cancer weighs in. Type 2 diabetes is not a reason to avoid it.

Who tends to benefit most

• Women under 60 or within 10 years of menopause whose hot flashes or night sweats disrupt daily life.
• Women at high risk of bone loss who also have symptoms.
• Early or premature menopause: menopause before 45, including primary ovarian insufficiency before 40. The Menopause Society recommends HRT at least until the usual age of menopause, about 52.
• Women whose main problem is vaginal dryness or painful sex: low-dose vaginal estrogen can be used at any age, for as long as needed.

The WHI results do not apply to women with early menopause. For them, HRT replaces hormones the body would normally still be making.

How long can you stay on HRT, and how do you stop?

There is no expiration date. The Menopause Society says an arbitrary age-based stopping rule is not clinically appropriate.

HRT does not need to be stopped routinely at 60 or 65 either. For healthy women with ongoing hot flashes, continuing past 65 is a reasonable option, with regular reviews of risks and benefits.

That matters because hot flashes often outlast expectations. In the large SWAN study of midlife women, frequent hot flashes lasted about 7.4 years on average.

Duration does change the breast cancer math with the combination. Estrogen alone did not raise breast cancer after seven years in the WHI, so longer use may suit women without a uterus.

Stopping

About half of women get hot flashes back after stopping. No study has settled whether tapering beats stopping at once, though many experts prefer a gradual taper.

Bone protection fades quickly once you stop. In the WHI, fracture risk returned to placebo levels after stopping, with no rebound above them.

Vaginal dryness tends to come back or worsen without estrogen. Low-dose vaginal estrogen can carry on after systemic HRT ends.

Effects of HRT that need a call right away

Most side effects are a nuisance, not a danger. The FDA patient leaflet for estrogen lists these warning signs as reasons to call your clinician right away:

• New breast lumps
• Unusual vaginal bleeding
• Changes in vision or speech
• Sudden new severe headaches
• Severe pain in your chest or legs, with or without shortness of breath, weakness and fatigue
• Swelling of the face, lips or tongue, with or without an itchy rash

Any bleeding after menopause needs checking, on HRT or not. On a combined regimen, spotting that continues past the first six months also needs a look. The everyday side effects are in HRT side effects.